Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

June 1, 2021, 8:16 a.m. EDT

Abbott adjusts financial outlook, citing lower demand for COVID-19 tests

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Abbott Laboratories (ABT)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Abbott /zigman2/quotes/203724446/composite ABT -1.60% fell 2.3% in premarket trading on Tuesday after the diagnostics company updated its financial outlook for 2021, citing declining demand for its COVID-19 tests. Abbott said it now expects earnings per share of $2.75 to $2.95 and adjusted EPS of $4.30 to $4.50. The company in April said it projected EPS of at least $3.74 and adjusted EPS of at least $5.00 for the full year. There are a number of reasons why COVID-19 testing volume is declining in the U.S., including increasing vaccination rates and recent guidance from the Centers for Disease Control and Prevention that told vaccinated Americans they do not need to get tested if they are exposed to someone infected with the virus. Abbott has developed 12 COVID-19 tests, which generated $2.2 billion in the first quarter of the year. Abbott's stock is up 6.5% for the year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.28% has gained 11.9%.

/zigman2/quotes/203724446/composite
US : U.S.: NYSE
$ 123.82
-2.01 -1.60%
Volume: 10.87M
Jan. 24, 2022 4:02p
P/E Ratio
30.64
Dividend Yield
1.52%
Market Cap
$222.50 billion
Rev. per Employee
$388,147
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,410.13
+12.19 +0.28%
Volume: 3.89B
Jan. 24, 2022 5:04p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.